Control of the inflammatory response and of tissue repair are major medical challenges encompassing a wide range of medical conditions. Existing treatments for multi-billion dollar markets in wound care, oncology support, women’s care, gastro-intestinal disease, oral care and dermatological care (including cosmetic applications) provide, at best, only partial relief and healing. In addition to seeking more comprehensive treatments, pharmaceutical companies are searching for natural solutions to provide breakthrough technologies that will address indications under-served by products currently available.
Izun Pharmaceuticals Corporation was founded in 2000 by Dr. Bill Levine and team, with the initial goal of providing an effective solution in the area of periodontal inflammation. The team successfully developed a proprietary, botanically-based platform technology which treats a wide range of inflammatory diseases, while simultaneously accelerating the body’s natural tissue repair process. Izun’s products are both efficacious and safe, providing novel solutions with potential to capitalize on multi-billion dollar market opportunities. Izun’s natural based products also enable multiple options with regard to regulatory filings.
Izun has launched two oral care products, one aimed at the professional dental care market and one for the OTC market. Two additional oral care products will be introduced worldwide for the OTC market in the coming year.
Izun has recently concluded a double-blinded placebo controlled Phase II clinical trial for the treatment of non-healing wounds. Izun is also currently conducting a second double-blinded placebo controlled Phase II clinical trial for the prevention of oral mucositis, a common side effect of chemotherapy and radiation therapy.
In addition Izun has recently initiated two clinical trials in the areas of Women’s Health care and Hemorrhoid control. Both these trials are early stage and are scheduled to be completed by Q4 2016.
Izun’s IP portfolio consists of 12 patents including three “composition of matter” patents. Five of the patents have already been granted.
Izun is a US corporation incorporated under the laws of Delaware, with a wholly-owned Jerusalem-based R&D subsidiary employing a staff of 17. In addition to an experienced and accomplished management team, Izun is supported by a world-class Board of Directors and team of scientific advisors and key opinion leaders.